Pfizer's Departure from ViiV: A Giant's Turnaround Amid the $400 Billion Patent Cliff
MNCs' Strategic Focus Consolidation
Time：
2026-01-26 09:23
Author：
xieyijun
Target revitalization, platform competition .....
Time：
2026-01-23 22:32
Author：
xieyijun
Small Nucleic Acids: Stepping into Their Boom Year
The New "Top Contender" in the 2026 Innovative Drug Race
Time：
2026-01-21 09:27
Author：
xieyijun
The Decisive Race for B7-H3: A Record of China's Innovative Drugs Overtaking the Curve
China's Biotechs Lead the Pack Globally
Time：
2026-01-20 13:21
Author：
xieyijun
Severed Wrist, Dormancy, Quantum Leap: The Rebirth of a Gene Therapy Company from Desperation
Dialogue with Zhao Chunlin, Founder of Anlong Biotech
Time：
2026-01-16 19:03
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务